Results 31 to 40 of about 40,497 (266)

Mechanisms of Cannabidiol (CBD) in Cancer Treatment: A Review

Biology, 2022
Cannabis sativa L. (Cannabis) and its bioactive compounds, including cannabinoids and non-cannabinoids, have been extensively studied for their biological effects in recent decades. Cannabidiol (CBD), a major non-intoxicating cannabinoid in Cannabis, has
Camren G. Heider, Sasha A. Itenberg, Jiajia Rao, Hang Ma, Xian Wu   +4 more
doaj   +1 more source

Neurotransmitter‐Defined Degeneration Patterns in Sporadic and C9orf72‐Associated Amyotrophic Lateral Sclerosis: Predilection to GABAergic, Serotonergic, Opioid, Glutamatergic, Endocannabinoid, and Microglial Systems—Implications for Therapy Development

Annals of Neurology, EarlyView.
Objective Amyotrophic lateral sclerosis (ALS) has a markedly distinctive clinical and neuroradiological signature, with the preferential involvement of specific brain networks and the apparent sparing of others. The molecular underpinnings of the strikingly selective anatomical vulnerability have not been fully elucidated to date despite the potential ...
Marlene Tahedl, We Fong Siah, Jasmin Lope, Jennifer C. Hengeveld, Mark A. Doherty, Russell L. McLaughlin, Orla Hardiman, Ee Ling Tan, Alison Toomey, Jana Kleinerova, Peter Bede   +10 more
wiley   +1 more source

An analysis of the cultivation, consumption and composition of home-grown cannabis following decriminalisation in the Australian Capital Territory

Scientific Reports
The Australian Capital Territory (ACT), a region that includes Australia’s capital, Canberra, decriminalised small-scale cannabis cultivation and possession in January 2020.
Cilla Zhou, Isobel Lavender, Rebecca Gordon, Danielle McCartney, Richard C. Kevin, Miguel A. Bedoya-Pérez, Iain S. McGregor   +6 more
doaj   +1 more source

Dosage Related Efficacy and Tolerability of Cannabidiol in Children With Treatment-Resistant Epileptic Encephalopathy: Preliminary Results of the CARE-E Study

Frontiers in Neurology, 2019
Purpose: There is uncertainty regarding the appropriate dose of Cannabidiol (CBD) for childhood epilepsy. We present the preliminary data of seven participants from the Cannabidiol in Children with Refractory Epileptic Encephalopathy (CARE-E) study ...
Richard J. Huntsman, Richard J. Huntsman, Richard Tang-Wai, Richard Tang-Wai, Jane Alcorn, Jane Alcorn, Stephanie Vuong, Bryan Acton, Bryan Acton, Scott Corley, Scott Corley, Robert Laprairie, Robert Laprairie, Andrew W. Lyon, Andrew W. Lyon, Simona Meier, Darrell D. Mousseau, Darrell D. Mousseau, Doris Newmeyer, Erin Prosser-Loose, Blair Seifert, Blair Seifert, Jose Tellez-Zenteno, Jose Tellez-Zenteno, Linda Huh, Edward Leung, Philippe Major   +26 more
doaj   +1 more source

Metabolic fate of drugs of abuse and new psychoactive substances: A pilot study on a novel workflow using a zebrafish embryo model combined with human microdosing

British Journal of Clinical Pharmacology, EarlyView.
Aim The aim of this study was to develop a novel workflow to identify human urine biomarkers for drugs of abuse and new psychoactive substances. Metabolites of amphetamine, cocaine, LSD, MDMA, methamphetamine, THC, MDMB‐CHMICA, and MDPPP were first identified in a zebrafish embryo (ZE) metabolism study followed by comparison to most abundant human ...
Simon K. Wellenberg, Tanja M. Gampfer, Lea Wagmann, Philip Schippers, Jennifer Herrmann, Rolf Müller, Folker Westphal, Markus R. Meyer   +7 more
wiley   +1 more source

Medical cannabis use in Australia seven years after legalisation: findings from the online Cannabis as Medicine Survey 2022–2023 (CAMS-22)

Harm Reduction Journal
Background Cannabis was legalised for medical purposes in 2016. Uptake was initially slow, but since 2019 there has been a large increase in the number of Australians who have been prescribed cannabis for medical reasons.
Llewellyn Mills, Jonathon C. Arnold, Anastasia Suraev, Sarah V. Abelev, Cilla Zhou, Thomas R. Arkell, Iain S. McGregor, Nicholas Lintzeris   +7 more
doaj   +1 more source

Cannabinoid combination targets NOTCH1-mutated T-cell acute lymphoblastic leukemia through the integrated stress response pathway

eLife
In T-cell acute lymphoblastic leukemia (T-ALL), more than 50% of cases display autoactivation of Notch1 signaling, leading to oncogenic transformation.
Elazar Besser, Anat Gelfand, Shiri Procaccia, Paula Berman, David Meiri   +4 more
doaj   +1 more source

Acute toxicity of ADB‐CHMINACA ‐ a case series of patients with pronounced central nervous symptoms including the posterior reversible encephalopathic syndrome

British Journal of Clinical Pharmacology, EarlyView.
Aim This report presents a series of 16 patients who were admitted to the emergency department following confirmed intake of the potent synthetic cannabinoid ADB‐CHMINACA. Methods The cases are drawn from a prospective observational study following the recreational use of synthetic cannabinoids.
Maren Hermanns‐Clausen, Michaela Sommer, Annette Zschiesche, Verena Angerer, Martin Scheu, Florian Eyer, Johannes Nadler, Volker Auwärter   +7 more
wiley   +1 more source

First‐in‐human, phase I, randomized, safety, pharmacokinetic, food‐effect and pharmacodynamic study of a tyrosine kinase 2/Janus kinase 1 inhibitor, SDC‐1801

British Journal of Clinical Pharmacology, EarlyView.
Aim The purpose of this study is to evaluate safety, tolerability, pharmacokinetics (PK), food‐effect (FE) and pharmacodynamics (PD) of an oral tyrosine kinase‐2 (TYK2)/Janus kinase‐1 (JAK1) inhibitor, SDC‐1801, in healthy adult participants. Methods This first‐in‐human study randomized 95 male and female participants.
Chris Brearley, Sam Francis, John Reader, Judi Proctor   +3 more
wiley   +1 more source

Efficacy and safety of cannabinoids in the treatment of spasticity in multiple sclerosis: A systematic review of randomized clinical trials

British Journal of Clinical Pharmacology, EarlyView.
Aims This work aimed to evaluate the efficacy and safety of cannabinoids for the treatment of MS‐related spasticity. Methods Systematic searches were conducted in PubMed, EMBASE, and LILACS on 2 December 2025. Randomized controlled trials evaluating natural or synthetic cannabinoids for MS‐related spasticity were included.
Letícia Hamm‐Buiar, Daniela Gorski, Marcela Harumi Kagueiama, Astrid Wiens   +3 more
wiley   +1 more source